Last reviewed · How we verify
DWC202313, DWC202314
DWC202313, DWC202314 is a botulinum toxin type A inhibitor Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development for Chronic sialorrhea, Upper limb spasticity.
DWC202313 and DWC202314 are botulinum toxin type A inhibitors.
DWC202313 and DWC202314 are botulinum toxin type A inhibitors. Used for Chronic sialorrhea, Upper limb spasticity.
At a glance
| Generic name | DWC202313, DWC202314 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | botulinum toxin type A inhibitor |
| Target | botulinum toxin type A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
They work by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation and reduced muscle spasms.
Approved indications
- Chronic sialorrhea
- Upper limb spasticity
Common side effects
- Injection site pain
- Muscle weakness
- Dysphagia
Key clinical trials
- A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension (PHASE3)
- Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition. (PHASE1)
- Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWC202313, DWC202314 CI brief — competitive landscape report
- DWC202313, DWC202314 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about DWC202313, DWC202314
What is DWC202313, DWC202314?
How does DWC202313, DWC202314 work?
What is DWC202313, DWC202314 used for?
Who makes DWC202313, DWC202314?
What drug class is DWC202313, DWC202314 in?
What development phase is DWC202313, DWC202314 in?
What are the side effects of DWC202313, DWC202314?
What does DWC202313, DWC202314 target?
Related
- Drug class: All botulinum toxin type A inhibitor drugs
- Target: All drugs targeting botulinum toxin type A
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Chronic sialorrhea
- Indication: Drugs for Upper limb spasticity
- Compare: DWC202313, DWC202314 vs similar drugs
- Pricing: DWC202313, DWC202314 cost, discount & access